Adi-001 clinical biomarker data demonstrate robust tissue trafficking and complete b cell depletion in secondary lymphoid tissue

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today announced adi-001 clinical biomarker data from the phase 1 glean trial which further reinforces the potential of adi-001 as a best-in-class allogeneic cell therapy for autoimmune diseases. notably, adi-001 demonstrated robust tissue trafficking resulting in high levels.
ACET Ratings Summary
ACET Quant Ranking